Abbott Laboratories
HealthcareNYSE:ABT · New York Stock Exchange
-$1.89 today
Vol 6.22M · Avg 12.84M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$45.1B of revenue converted into $6.3B of net income for the selected period. Gross margin is 56.4% and net margin is 13.9%, showing how much revenue survives after costs and taxes. EPS is $3.59, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.3B +5.7% | $42.0B +4.6% | $40.1B -8.1% | $43.7B +1.3% | $43.1B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $19.7B -4.4% | $20.6B +2.8% | $20.1B -5.9% | $21.3B +7.4% | $19.9B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $24.6B +15.4% | $21.3B +6.4% | $20.0B -10.2% | $22.3B -3.8% | $23.2B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 55.5% +4.7pp | 50.8% +0.9pp | 50.0% -1.2pp | 51.1% -2.8pp | 53.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $3.0B +4.7% | $2.8B +3.8% | $2.7B -4.7% | $2.9B +4.2% | $2.7B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $12.4B +6.2% | $11.7B +7.1% | $10.9B -2.0% | $11.1B -1.5% | $11.3B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $16.6B +14.6% | $14.5B +6.4% | $13.6B -2.6% | $14.0B -0.4% | $14.0B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.7B -14.7% | $3.2B -0.8% | $3.2B -0.7% | $3.3B -7.7% | $3.5B | $374.2M | $1.2B | $631.8M |
| EBITDA | $11.6B +6.6% | $10.8B +2.2% | $10.6B -10.8% | $11.9B -2.2% | $12.2B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 26.1% +0.2pp | 25.8% -0.6pp | 26.4% -0.8pp | 27.2% -1.0pp | 28.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $8.0B +17.9% | $6.8B +6.1% | $6.4B -23.0% | $8.4B -9.1% | $9.2B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 18.2% +1.9pp | 16.3% +0.2pp | 16.0% -3.1pp | 19.2% -2.2pp | 21.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $230.0M -33.1% | $344.0M -10.6% | $385.0M +110.4% | $183.0M +325.6% | $43.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $341.0M -43.4% | $603.0M -13.6% | $698.0M +121.6% | $315.0M -23.2% | $410.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $418.0M +122.3% | $188.0M -17.9% | $229.0M +508.9% | -$56.0M +94.3% | -$989.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $8.5B +20.7% | $7.0B +5.2% | $6.7B -19.8% | $8.3B +1.2% | $8.2B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 19.1% +2.4pp | 16.7% +0.1pp | 16.6% -2.4pp | 19.0% -0.0pp | 19.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.9B +130.4% | -$6.4B -779.0% | $941.0M -31.5% | $1.4B +20.4% | $1.1B | $1.3B | -$1.6B | $745.2M |
| Net Income | $6.5B -51.3% | $13.4B +134.2% | $5.7B -17.5% | $6.9B -2.0% | $7.1B | $4.9B | $4.8B | $4.7B |
| Net Margin | 14.7% -17.2pp | 31.9% +17.7pp | 14.3% -1.6pp | 15.9% -0.5pp | 16.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $4 -51.2% | $8 +132.4% | $3 -16.2% | $4 -0.8% | $4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $4 -51.3% | $8 +133.6% | $3 -16.4% | $4 -0.8% | $4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.7B +0.9% | $1.7B -0.1% | $1.7B -1.1% | $1.8B -1.2% | $1.8B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.7B -0.1% | $1.7B -0.1% | $1.7B -0.9% | $1.8B -1.4% | $1.8B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
UnitedHealth Group Incorporated
NYSE:UNH
$370.42B
Merck & Co., Inc.
NYSE:MRK
$296.05B
Novartis AG
NYSE:NVS
$292.70B
Novo Nordisk A/S
NYSE:NVO
$196.75B
Thermo Fisher Scientific Inc.
NYSE:TMO
$174.38B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.38B
Intuitive Surgical, Inc.
NASDAQ:ISRG
$144.53B
Stryker Corporation
NYSE:SYK
$120.34B
Medtronic plc
NYSE:MDT
$103.17B
Boston Scientific Corporation
NYSE:BSX
$69.91B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ABT generate?
Abbott Laboratories (ABT) reported $44.33B of revenue in fiscal 2025.
Is ABT profitable?
Abbott Laboratories (ABT) reported $6.52B of net income, with a net margin of 14.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.